Key result
Epicardial pulsed field ablation of ganglionated plexi during surgery extends AERP by ~21%.
Why the study?
Modulation of the cardiac autonomic nervous system via pulsed field ablation of ganglionated plexi is promising for atrial fibrillation, but clinical feasibility and safety during cardiac surgery needed evaluation.
Does epicardial ganglionated plexi ablation with pulsed field electroporation prolong atrial effective refractory period in patients undergoing CABG?
Does epicardial ganglionated plexi ablation with pulsed field electroporation prolong atrial effective refractory period in patients undergoing CABG?
Epicardial ablation of ganglionated plexi using pulsed field electroporation during CABG is safe, feasible, and acutely prolongs the atrial effective refractory period.
Answers are grounded in this paper and cite their sources.
Acute AERP prolongation with pulsed-field GP ablation in CABG is hypothesis-generating; leaves open clinical benefit and need for RCTs.
BACKGROUND: Modulation of the cardiac autonomic nervous system (ANS) is a promising adjuvant therapy in the treatment of atrial fibrillation (AF). In pre-clinical models, pulsed field (PF) energy has the advantage of selectively ablating the epicardial ganglionated plexi (GP) that govern the ANS. This study aims to demonstrate the feasibility and safety of epicardial ablation of the GPs with PF during cardiac surgery with a primary efficacy outcome of prolongation of the atrial effective refractory period (AERP). METHODS: In a single-arm, prospective analysis, patients with or without a history of AF underwent epicardial GP ablation with PF during coronary artery bypass grafting (CABG). AERP was determined immediately pre- and post- GP ablation to assess cardiac ANS function. Holter monitors were performed to determine rhythm status and heart rate variability (HRV) at baseline and at 1-month post-procedure. RESULTS: Of 24 patients, 23 (96%) received the full ablation protocol. No device-related adverse effects were noted. GP ablation resulted in a 20.7 ± 19.9% extension in AERP (P < 0.001). Post-operative AF was observed in 7 (29%) patients. Holter monitoring demonstrated an increase in mean heart rate (74.0 ± 8.7 vs. 80.6 ± 12.3, P = 0.01). There were no significant changes in HRV. There were no study-related complications. CONCLUSIONS: This study demonstrates the safety and feasibility of epicardial ablation of the GP using PF to modulate the ANS during cardiac surgery. Large, randomized analyses are necessary to determine whether epicardial PF ablation can offer a meaningful impact on the cardiac ANS and reduce AF. TRIAL REGISTRATION: Clinical trial registration: NCT04775264.
No takes yet. Share an insight, caveat, or question.
Musikantow et al. (2023) studied Coronary artery disease requiring coronary artery bypass grafting (CABG) (n=24). Epicardial ganglionated plexi ablation with pulsed field electroporation was evaluated on Prolongation of the atrial effective refractory period (AERP) (p=<0.001). Epicardial ablation of the ganglionated plexi using pulsed field electroporation during cardiac surgery resulted in a 20.7% extension in the atrial effective refractory period.
Synapse has enriched 10 related papers. Consider them for comparative context: